PURPOSE: This study was undertaken to investigate the efficacy of red blood cell transfusion (RBCT) at reversing the deleterious effects of moderate anemia in critically ill, non-bleeding patients. METHODS: This was a retrospective, pair-matched (ratio 1:1) cohort study. Non-bleeding critically ill patients with moderate anemia (nadir hemoglobin level between 70 and 95 g/l), admitted to the ICU over a 27-month period, were included. Anemic patients were included upon meeting five matching criteria of having the same nadir hemoglobin (±5 g/l), APACHE II score (±5), SOFA score (±2), admission diagnostic group, and age (±5 years). Outcome events occurring over the whole ICU stay and after RBCT were collected. After hospital discharge, all patients had a 2-year follow-up period. RESULTS: Two hundred fourteen non-transfused anemic patients (NTAPs) were successfully matched with 214 transfused anemic patients (TAPs). In addition to the matching criteria, at baseline, both groups were homogenous with respect to multiple comorbidities. Compared with TAPs, NTAPs showed significantly lower rates of hospital mortality (21 vs.13 %, respectively; p < 0.05) and ICU re-admission (7.4 vs. 1.9 %, respectively; p < 0.05). Additionally, NTAPs had significantly lower rates of nosocomial infection (12.9 vs. 6.7 %, respectively; p < 0.05) and acute kidney injury (24.8 vs. 16.7 %, respectively; p < 0.05). Similar results were obtained in subgroup analysis where only more anemic patients (68 matched pairs) or patients with cardiovascular comorbidities (63 matched pairs) were considered. CONCLUSIONS: RBCT does not improve the clinical outcome in non-bleeding critically ill patients with moderate anemia.
PURPOSE: This study was undertaken to investigate the efficacy of red blood cell transfusion (RBCT) at reversing the deleterious effects of moderate anemia in critically ill, non-bleedingpatients. METHODS: This was a retrospective, pair-matched (ratio 1:1) cohort study. Non-bleeding critically illpatients with moderate anemia (nadir hemoglobin level between 70 and 95 g/l), admitted to the ICU over a 27-month period, were included. Anemicpatients were included upon meeting five matching criteria of having the same nadir hemoglobin (±5 g/l), APACHE II score (±5), SOFA score (±2), admission diagnostic group, and age (±5 years). Outcome events occurring over the whole ICU stay and after RBCT were collected. After hospital discharge, all patients had a 2-year follow-up period. RESULTS: Two hundred fourteen non-transfused anemicpatients (NTAPs) were successfully matched with 214 transfused anemicpatients (TAPs). In addition to the matching criteria, at baseline, both groups were homogenous with respect to multiple comorbidities. Compared with TAPs, NTAPs showed significantly lower rates of hospital mortality (21 vs.13 %, respectively; p < 0.05) and ICU re-admission (7.4 vs. 1.9 %, respectively; p < 0.05). Additionally, NTAPs had significantly lower rates of nosocomial infection (12.9 vs. 6.7 %, respectively; p < 0.05) and acute kidney injury (24.8 vs. 16.7 %, respectively; p < 0.05). Similar results were obtained in subgroup analysis where only more anemicpatients (68 matched pairs) or patients with cardiovascular comorbidities (63 matched pairs) were considered. CONCLUSIONS: RBCT does not improve the clinical outcome in non-bleeding critically illpatients with moderate anemia.
Authors: Jeffrey L Carson; Michael L Terrin; Helaine Noveck; David W Sanders; Bernard R Chaitman; George G Rhoads; George Nemo; Karen Dragert; Lauren Beaupre; Kevin Hildebrand; William Macaulay; Courtland Lewis; Donald Richard Cook; Gwendolyn Dobbin; Khwaja J Zakriya; Fred S Apple; Rebecca A Horney; Jay Magaziner Journal: N Engl J Med Date: 2011-12-14 Impact factor: 91.245
Authors: Aryeh Shander; Arlene Fink; Mazyar Javidroozi; Jochen Erhard; Shannon L Farmer; Howard Corwin; Lawrence Tim Goodnough; Axel Hofmann; James Isbister; Sherri Ozawa; Donat R Spahn Journal: Transfus Med Rev Date: 2011-04-17
Authors: Victor A Ferraris; Jeremiah R Brown; George J Despotis; John W Hammon; T Brett Reece; Sibu P Saha; Howard K Song; Ellen R Clough; Linda J Shore-Lesserson; Lawrence T Goodnough; C David Mazer; Aryeh Shander; Mark Stafford-Smith; Jonathan Waters; Robert A Baker; Timothy A Dickinson; Daniel J FitzGerald; Donald S Likosky; Kenneth G Shann Journal: Ann Thorac Surg Date: 2011-03 Impact factor: 4.330
Authors: Richard B Weiskopf; John Feiner; Harriet Hopf; Jeremy Lieberman; Heather E Finlay; Cheng Quah; Joel H Kramer; Alan Bostrom; Pearl Toy Journal: Anesthesiology Date: 2006-05 Impact factor: 7.892
Authors: Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Edward Abraham; Neil R MacIntyre; M Michael Shabot; Mei-Sheng Duh; Marc J Shapiro Journal: Crit Care Med Date: 2004-01 Impact factor: 7.598
Authors: Manuel Quintana Díaz; Alberto M Borobia; José A García Erce; Charbel Maroun-Eid; Sara Fabra; Antonio Carcas; Jesus Frías; Manuel Muñoz Journal: Blood Transfus Date: 2016-07-07 Impact factor: 3.443
Authors: Adam Gyedu; Stephanie K Goodman; Robert Quansah; Maxwell Osei-Ampofo; Peter Donkor; Charles Mock Journal: Injury Date: 2021-01-21 Impact factor: 2.586
Authors: Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay Journal: Intensive Care Med Date: 2013-12-13 Impact factor: 17.440
Authors: Jennifer A Muszynski; Philip C Spinella; Jill M Cholette; Jason P Acker; Mark W Hall; Nicole P Juffermans; Daniel P Kelly; Neil Blumberg; Kathleen Nicol; Jennifer Liedel; Allan Doctor; Kenneth E Remy; Marisa Tucci; Jacques Lacroix; Philip J Norris Journal: Transfusion Date: 2016-10-02 Impact factor: 3.157